EUVIMEDEUVIMED entdecken
Crossref

Defining Prognostic Markers and Clinical Outcomes in Epithelioid Malignant Peripheral Nerve Sheath Tumor

Lee P Richman, Phillip D Michaels, Corrine Nief, Vickie Y Jo, Dana J Hariri, G Petur Nielsen, Fei Dong, Emanuele Mazzola, Jason L Hornick, Inga-Marie Schaefer

Modern Pathology · 2026-05 · 39 (5) · 100993

DOI: 10.1016/j.modpat.2026.100993 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026-05. Verfasst von Lee P Richman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Neurofibrosarcoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: American Association for Cancer Research, Brigham and Women's Hospital, Instituto Português de Oncologia do Porto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelioid malignant peripheral nerve sheath tumor (EMPNST) is recognized as a distinct entity in the 2026 World Health Organization classification, defined by characteristic morphology and frequent SMARCB1 (INI1) loss, which differentiates it from conventional MPNST. Limited data suggest EMPNST may have a more favorable prognosis, but prognostic markers remain undefined. We studied 78 primary EMPNSTs and compared them with 60 conventional MPNSTs. Patients with EMPNST included 41 females and 37 males, with a median age of 45 (range, 6-84) years. Necrosis was observed in 20% of cases, cytologic atypia was mild (25%), moderate (57%), or severe (18%), and mitoses ranged from 0 to 42/10 (median 7/10) high-power fields. SMARCB1 loss was observed in 81% of EMPNSTs and correlated with prominent nucleoli (64%, P 5 cm, mitoses > 7 of 10 high-power fields, and necrosis predicted poor outcomes (HR, 4.1; 95% CI, 1.4-12). In conclusion, EMPNST tumor size and mitotic activity are key prognostic factors, supporting a simple risk stratification model. SMARCB1 inactivation is the most frequent genomic event, followed by gains at 2q35 potentially targeting XRCC5, highlighting molecular underpinnings for this distinct sarcoma subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorNeurofibrosarcomaHumansFemaleMaleAdultAdolescentMiddle AgedChildPrognosisYoung AdultSMARCB1 ProteinAgedAged, 80 and over

Stichwörter der Autor:innen

2q35SMARCB1XRCC5epithelioid malignant peripheral nerve sheath tumorprognosissurvival

Substanzen

Biomarkers, TumorSMARCB1 ProteinSMARCB1 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Department of Internal Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Department of Pathology, Stanford University, Palo Alto, California.
  • Department of Data Science, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: ischaefer@bwh.harvard.edu.

Förderung

  • American Association for Cancer Research
  • Brigham and Women's Hospital
  • Instituto Português de Oncologia do Porto
  • Anschutz Medical Campus, University of Colorado
  • University of Minnesota
  • Università di Bologna
  • St Joseph Hospital
  • Phoenix Children's Hospital

Zitieren

APA

Richman, L. P., Michaels, P. D., Nief, C., Jo, V. Y., Hariri, D. J., Nielsen, G. P., Dong, F., Mazzola, E., Hornick, J. L., & Schaefer, I. M. (2026). Defining Prognostic Markers and Clinical Outcomes in Epithelioid Malignant Peripheral Nerve Sheath Tumor. Modern Pathology, 39(5), 100993. https://doi.org/10.1016/j.modpat.2026.100993

Vancouver

Richman LP, Michaels PD, Nief C, Jo VY, Hariri DJ, Nielsen GP, et al. Defining Prognostic Markers and Clinical Outcomes in Epithelioid Malignant Peripheral Nerve Sheath Tumor. Modern Pathology. 2026;39(5):100993. doi:10.1016/j.modpat.2026.100993

BibTeX
@article{Richman2026,
  author = {Richman, Lee P and Michaels, Phillip D and Nief, Corrine and Jo, Vickie Y and Hariri, Dana J and Nielsen, G Petur and Dong, Fei and Mazzola, Emanuele and Hornick, Jason L and Schaefer, Inga-Marie},
  title = {Defining Prognostic Markers and Clinical Outcomes in Epithelioid Malignant Peripheral Nerve Sheath Tumor},
  journal = {Modern Pathology},
  year = {2026},
  volume = {39},
  number = {5},
  pages = {100993},
  doi = {10.1016/j.modpat.2026.100993}
}
Kostenlos starten →